EP3174390A1 - Composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure - Google Patents

Composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure

Info

Publication number
EP3174390A1
EP3174390A1 EP15745431.5A EP15745431A EP3174390A1 EP 3174390 A1 EP3174390 A1 EP 3174390A1 EP 15745431 A EP15745431 A EP 15745431A EP 3174390 A1 EP3174390 A1 EP 3174390A1
Authority
EP
European Patent Office
Prior art keywords
pyrrolidine
composition according
oxo
carboxylic acid
glucoprotamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15745431.5A
Other languages
German (de)
English (en)
Inventor
Bernhard HIRT
Claus ZEYHER
Corrina GLEISER
Lothar Just
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of EP3174390A1 publication Critical patent/EP3174390A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Definitions

  • composition for modulating the activity of non-structural proteins Composition for modulating the activity of non-structural proteins
  • the present invention relates to a composition for modulating the activity of non-structural proteins and a compound contained therein.
  • the modulation, in particular inhibition of the activity of proteins is in various areas of science, medicine and technology of central importance.
  • the inactivation of functional proteins also plays a key role in the field of industrial fermentation and bioprocess engineering, agriculture and agricultural science as well as in medical applications, for example in connection with the inactivation of toxins, hormones or inflammatory mediators.
  • aldehydes such as formaldehyde
  • detergents with a demonstrated denaturing effect on proteins, such as sodium dodecyl sulfate (SDS), or other ionic surfactants used with a chain length of C 12 .
  • SDS sodium dodecyl sulfate
  • aldehydes have a high acute toxicity. They are carcinogenic, mutagenic and highly sensitizing. Aldehydes have recently come under criticism again.
  • aldehydes not only have a great effect Proteins with enzymatic action but also on structural proteins, by changing them in their structure by cross-linking.
  • SDS and ionic surfactants with a chain length of C 12 are prone to precipitate and thus to loss of activity in the medium of increased electrolyte concentration, especially in combination with metal ions such as Ca ++ , Mg ++ or K + . They are thus unsuitable for use in complex biological systems.
  • the strongly denaturing detergents are considered to be highly sensitizing and are thus harmful to health.
  • Non-denaturing detergents, such as fatty alcohols such as Triton X100 are not suitable for inactivating functional proteins and are therefore used for protein insolubilization.
  • composition containing a 5-oxo-pyrrolidine-2-carboxylic acid derivative of the formula I is achieved by a composition containing a 5-oxo-pyrrolidine-2-carboxylic acid derivative of the formula I.
  • Ri is selected from the group consisting of:
  • R 2 and R 3 are selected from the group consisting of:
  • X O or S; for modulating the activity of non-structural proteins.
  • a 5-oxo-pyrrolidine-2-carboxylic acid derivative has excellent properties to modulate the activity of non-structural proteins.
  • the 5-oxo-pyrrolidine-2-carboxylic acid derivative is significantly less hazardous to health than the currently used aldehydes or detergents or surfactants. It has proven to be of particular advantage in this case that the recognized effects are dose-dependent.
  • the modulation of the activity of the non-structural proteins can therefore be adjusted selectively in the desired strength and duration and thus opens up a variety of possible applications.
  • 5-Oxo-pyrrolidine-2-carboxylic acid derivatives can be prepared by methods well known in the art, such as for example in a method described in DE 3 410 956. Furthermore, the inventors have been able to develop a novel process for the preparation of 5-oxo-pyrrolidine-2-carboxylic acid derivatives, which is associated with an even lower production cost.
  • a “derivative" of 5-oxo-pyrrolidine-2-carboxylic acid includes a derivative thereof which can be obtained by chemical modification thereof.
  • the derivatives still have the heterocycle of the pyrrolidine, but may in particular differ from each other in their alkyl radicals.
  • the heterocycle of the pyrrolidine may have functional groups at various positions, such as preferably at positions 3 and 4. According to the invention, both the S-enantiomer and the R-enantiomer or the racemat formed therefrom are included.
  • the "5-oxo-pyrrolidine-2-carboxylic acid derivative” further includes a 5-oxo-pyrrolidine-2-carboxylic ester derivative, which is also referred to as a pyrroglutamate ester derivative.
  • non-structural proteins are understood as meaning proteins which do not serve as builders in tissues or cells of living beings. Non-structural proteins are therefore especially those proteins with catalytic function, such as enzymes, but also peptides, peptide hormones, receptors, cytokines, peptidic toxins, etc.
  • the invention is also suitable for modulating the catalytic activity of nucleic acid molecules, such as ribozymes, aptamers, siRNA, etc., as well as the activity of steroid hormones.
  • nucleic acid molecules such as ribozymes, aptamers, siRNA, etc.
  • a change is understood to mean a change.
  • a "modulation of the activity of non-structural proteins” is understood to mean the deliberate change in the function of the proteins carried out in a natural environment.
  • composition according to the invention apply to the 5-oxo-pyrrolidine-2-carboxylic acid derivative accordingly.
  • the modulation is an inhibition, preferably a deactivation.
  • This measure has the advantage that protein activities, for example enzymatic or catalytic nature, specifically reduced or even eliminated, whereas structural proteins are still able to give cells their shape and tissues their strength and elasticity. This is of particular importance in the area of cell and tissue preservation.
  • the non-structural protein is an enzyme
  • composition according to the invention or the 5-oxo-pyrrolidine-2-carboxylic acid derivative according to the invention purposefully inhibits or eliminates catalytic activities, whereas the structural proteins still retain their biomechanical and physical properties exercise.
  • the enzyme is selected from the group consisting of: oxidoreductases, such as, for example, alcohol hydro genases; Hydrolases such as alkaline phosphatase, endoproteases, RNases, DNases, lipases; transferases; lyases; isomerases; Ligases.
  • This measure has the advantage that targeted such enzymes are inhibited or completely eliminated, which are in the field of preservation or medical implications of particular importance.
  • the 5-oxo-pyrrolidine-2-carboxylic acid derivative is glucoprotamine of the formula II:
  • Glucoprotamine is a multicomponent substance. The most important two components and main active substances of glucoprotamine are the (2S) -pyrrolidine-5-oxocarboxamide, N-3- (dodecylamino) -propyl and the (2S) -pyrrolidine-5-oxo-carboxylic acid amide, N-3- ( tetradecylamino) propyl.
  • Glucoprotamine (CAS No.
  • glucoprotamine has the structural formula C20H39N3O2 and the molecular weight 353.55, with a C14 residue the structural formula C22H43N3O2 and the molecular weight 381, 61.
  • Glucoprotamin is characterized by its insensitivity to a high protein load, low toxicity or ecotoxicity, it is fast and completely degradable. It is easily soluble in water and is stable for a long time. Thus, no efficacy loss could be detected in a study even after eight years of storage. It is sold, for example, by the company Ecolab GmbH, Dusseldorf.
  • composition according to the invention or the 5-oxo-pyrrolidine-2-carboxylic acid derivative is intended for use as a preservative and / or fixative.
  • the inventors were able to show that the composition or the 5-oxo-pyrrolidine-2-carboxylic acid derivative is suitable for the aldehyde-free preservation of tissues, organs and whole body preparations.
  • the extensive and simultaneous inactivation of several classes of enzymes involved in the lysing of tissues allows a novel conservation of biological material.
  • the inventors were able to prove that both organ and whole-body pre- parate after treatment with the composition according to the invention in their structural integrity can hardly be changed. Even after several months whole body preparations with a realistic feel could be preserved in unprecedented quality.
  • compositions or the 5-oxo-pyrrolidine-2-carboxylic acid derivative as a preservative for cosmetic, food or pharmaceutical products.
  • the composition or the 5-oxo-pyrrolidine-2-carboxylic acid derivative is designed for use as a medicament.
  • the inhibitory effect on non-structural proteins recognized by the inventors makes the composition or the 5-oxo-pyrrolidine-2-carboxylic acid derivative particularly suitable for use as a drug.
  • the composition according to the invention or the 5-oxo-pyrrolidine-2-carboxylic acid derivative can be targeted for inhibiting the activity of hormones, antibodies, cytokines, interferons, interleukins, chemokines, growth factors, colony-stimulating factors, tumor necrosis factors, receptors, ribozymes and use other disease-mediating enzymes.
  • the invention can be used selectively in chronic inflammatory diseases, e.g. by creating a inflammatory environment, for example in chronic rheumatoid arthritis. This can be done, for example, by intra-articular injection of the composition according to the invention or of the 5-oxo-pyrrolidine-2-carboxylic acid derivative or lavage herewith.
  • chronic inflammatory bowel diseases such as Crohn's disease or ulcerative colitis, chronic obstructive pulmonary disease, chronic skin and mucous membrane diseases, or autoimmune diseases.
  • the invention is used, for example in the context of a Wunddebridgement or a lavage.
  • the composition according to the invention or the 5-oxo-pyrrolidine-2-carboxylic acid derivative can also be used in the field of oncology, immunology and allergology, for example for cytokine or chemokinin activation or inactivation of hormones.
  • the composition of the invention or the 5-oxo-2-pyrrolidine-carboxylic acid derivative application can be used to inactivate odor-causing enzymes and thus be used as part of deodorants.
  • the composition according to the invention or of the 5-oxo-pyrrolidine-2-carboxylic acid derivative it is possible to selectively inactivate elastases and / or collagenases and thus prevent aging of the skin.
  • the composition according to the invention or the 5-oxo-pyrrolidine-2-carboxylic acid derivative can therefore be used as a constituent of creams, ointments, lotions or other topically administrable formulations.
  • the composition or the 5-oxo-2-pyrrolidine derivative is designed for use as a biocide, preferably selected from the group consisting of: insecticide, ovicide, acaricide, molluscicide, nematicide, anthelminthic , Herbicide, algicide, graminicide and arborizid.
  • composition or the 5-oxo-2-pyrrolidine-carboxylic acid derivative can be used for targeted application in the life and agricultural sciences and there due to their modulating or
  • the composition of the invention or the inventive 5-oxo-pyrrolidine-2-carboxylic acid derivative is designed for use as a fermentation aid.
  • composition according to the invention or the 5-oxo-pyrrolidine-2-carboxylic acid derivative in the creation of an enzyme-free inflammatory environment is used.
  • the composition or the 5-oxo-pyrrolidine-2-carboxylic acid derivative is designed for use as a surface coating agent.
  • functional groups can be attached to positions 3 and 4 of the pyrrolidine ring, such as OH, SH or photoreactive groups.
  • This allows the use of the 5-oxo-pyrrolidine-2-carboxylic acid derivative or the composition according to the invention as a surface coating in medical and biotechnical product development and application.
  • coated medical devices such as thread materials, stents, joint implants and wound dressings are thought.
  • the coating can be realized, for example, via adhesion but also via covalent bonding or immobilization of the 5-oxo-pyrrolidine-2-carboxylic acid derivative.
  • Fig. 1 Reaction sequence of the reaction of alcohol dehydrogenase (ADH).
  • the kinetics of the control without glucoprotamine shows that the substrate / coenzyme used in the test was present in saturating concentration.
  • Fig. 2 Concentration-dependent modulation of alkaline phosphatase
  • ALP glucoprotamine
  • FIG. 3 Inactivation of the endoproteases by glucoprotamine compared to
  • FIG. 4 Real-time determination of the inactivation of RNases by glucoprotamine.
  • Fig. 5 Real-time determination of the inactivation of lipases by glucoprotamine.
  • Fig. 6 Conservation of organs from the rat (Wistar, postnatal, 31 days) with glucoprotamine compared to the preservation with formalin.
  • Fig. 7 Open thorax situs of a body donor after transarterial infusion with glucoprotamine, 7 months post-mortem.
  • Fig. 8 Opened left ventricle of a body donor after transarterial infusion with glucoprotamine, 7 months post-mortem.
  • the inventors have developed an improved process for producing a 5-oxo-pyrrolidine-2-carboxylic acid derivative.
  • 5-oxo-pyrrolidine-2-carboxylic acid derivatives preferably the S-enantiomer, but also the R-enantiomer or racemate.
  • Ri linear alkyl radical with Ci -6 ; preferably Ci;
  • R 2 linear alkyl radical having the chain length C 2 - 22 , wherein here are singly and polyunsaturated alkyl radicals included.
  • Ri linear alkyl radical with Ci -6 ; preferably Ci;
  • R 2 linear alkyl or acyl radical having the chain length C 2 - 22 , wherein here are singly and polyunsaturated alkyl and acyl radicals included.
  • the reaction requires only a preferred temperature of 60 ° C, a preferred reaction time of 60 min. and a preferred pressure of 300-350 mbar. Methanol is distilled off.
  • the inventors were able to successfully prepare the 5-oxo-pyrrolidine-2-carboxylic acid derivative called glucoprotamine.
  • the starting substances 5-oxo-pyrrolidine-2-carboxylic acid derivatives and N-substituted monoamine, diamine and fatty amide derivatives are to be modified with the aim of influencing the active ingredient kinetics, active ingredient dynamics and active ingredient performance of the synthesis products.
  • the starting substance 5-oxo-pyrrolidine-2-carboxylic acid can be modified at positions 3 and 4 of the pyrrolidine ring.
  • attachment of protected hydroxyl or sulfhydryl groups to positions 3 and / or 4 of the pyrrolidine ring allows coupling of the active substance to surfaces of various materials. This allows the use of the active ingredients produced as a surface coating.
  • Scheme 5 Modification of the 5-oxo-pyrrolidine-2-carboxylic acid derivative by attachment of (a) hydroxyl and / or (b) sulfhydryl groups. Shown is the example of a hydroxyl group at position 4 and a sulfhydryl group at position 3.
  • Ri is a linear alkyl group with C1 -6; preferably C1.
  • the attachment of, for example, photoreactive groups may allow for conditioned modification of the active substance.
  • the mild new production process also makes it possible, for example, to use alkyl radicals of different chain lengths or else in the unsaturated state. was standing. Modification of the chain length can lead to an altered drug profile.
  • Oxidoreductases (Enzyme Class 1, EC1)
  • ADH alcohol dehydrogenase
  • NAD + nicotinamide adenine dinucleotide
  • ALP alkaline phosphatase
  • pNPP p-nitrophenyl phosphate
  • the activity of endoproteases was also determined using a fluorescence resonance energy transfer (FRET) peptide library containing over 2.5 million peptides (Kapprell et al. (201 1), Assay and Drug Development Technologies).
  • FRET fluorescence resonance energy transfer
  • the principle of this protease detection is based on the MCA fluorophore as donor and the 2,4-dinitrophenyl moiety as quencher coupled to the peptides. Once the protease cleaves the peptides, the donor and quencher are separated and a strong fluorescent signal is generated. The protease activity is thus directly proportional to the increase in the relative fluorescence intensity.
  • the activity of RNases can be determined using a cleavable fluorescence-labeled RNase substrate according to the FRET principle (RNaseAlert Lab Test Kit, Applied Biosystems, Germany).
  • the substrate is a modified RNA oligonucleotide that emits green fluorescence when cleaved by RNases.
  • the RNase activity is thus directly proportional to the increase in fluorescence intensity.
  • RNase A about 2 ⁇ g
  • RNaseAlert Lab Test Kit a commercial test system
  • the positivity control was treated with nuclease-free water instead of glucoprotamine and otherwise treated the same.
  • the fluorescence-labeled substrate was determined in real time using an Infinite M200 Microplate Reader.
  • nuclease-free water positive control
  • 2.6% glucoprotamine Figure 4B
  • RNaseZap commercial RNase decontamination solution from Blyde Biosystems, Figure 4C
  • RNase-ExitusPlus commercial RNase decontamination solution from AppliChem, Germany, Fig. 4D
  • nuclease-free water After the surfaces had dried, 500 ⁇ l of nuclease-free water were distributed uniformly on the work surfaces, incubated for one minute and withdrawn again using a pipette. 45 ⁇ of these four different approaches were provided with the fluorescence-labeled substrate and the change in the fluorescence intensity and thus the RNase activity using an Infinite M200 microplate reader (Tecan, Switzerland) determined in real time (Fig. 4 BD).
  • the treatment of the work surfaces with glucoprotamine leads to inactivation of the RNases present in the sweat and saliva and thus to a decontamination of the working surface. These Complete decontamination is comparable to the previously commercially available decontamination solutions.
  • an increase in fluorescence intensity as a function of time and thus a high RNase activity could be observed.
  • the lipase hydrolyzes arachidonoyl-1-thioglycerol to arachidonic acid and thioglycerol.
  • Thioglycerol reacts with the thiol fluorometric detector to give a highly fluorescent product which can be analyzed at an excitation wavelength of 380 to 390 nm and an emission wavelength of 510 to 520 nm.
  • the bovine milk lipoprotein lipases are inactivated by glucoprotamine.
  • 200 mg of human gluteal subcutaneous adipose tissue were removed post mortem and this with ice-cold PBS using a Precellys ceramic kit 1 .4 / 2.1 mm (PeqLab, Germany) in a mini-workstation homogenizer (PeqLab) for 4 ⁇ 10 seconds Homogenized at 5,000 rpm. The homogenate was then centrifuged for 10 minutes at 10,000 xg and 10 ⁇ of the middle phase taken. This sample was either spiked with 2.6% glucoprotamine or added directly (positive control) to the assay buffer and thiol detector.
  • glucoprotamine organs were taken from adult Wistar rats (postnatal, 31 days) and photographed. Subsequently, the organs were incubated in either 2.6% glucoprotamine or 4% formalin for 7 days. Thereafter, the organs were stored for a further 25 days without preservative solutions, uncovered at room temperature, and then re-photographed and evaluated (Figure 6). Glucoprotamin-conserved organs exhibited comparable preservation to formalin-fixed organs, but retained their tissue elasticity.
  • the whole body preparation was wrapped in a damp cloth with the above solution and sealed in a film. Tissue consistency and tissue condition were monitored at 2 weeks, 1 month, 3 months, and 7 months.
  • a diagnostic laparoscopy and then an open-surgical examination via a median laparotomy were performed. Result: The gastrointestinal tract was intact without signs of lysis. A microbiological smear examination showed a sterility of the intraperitoneal space in the area of the large intestine as well as the recess of the cave.
  • an anatomical cover osteoporosis preparation was performed ( Figures 7 and 8) to open and inspect the entire abdominal space and thorax space.
  • the organs were all preserved. Even organs with a per se high content of digestive enzymes, such as the pancreas, retained their morphological integrity.
  • the left heart was opened and the endocardial space inspected (Fig. 8). Even fine structures, e.g. Flaps, Chordae tendineae, were found to be realistic.
  • the inventors provide with a 5-oxo-pyrrolidine-2-carboxylic acid derivative, such as, for example, the glucoprotamine, a versatile active ingredient ready, with the targeted modulation of the activity of non-structural proteins, preferably can be inhibited.
  • the substance is significantly less harmful to health than the currently used aldehydes, detergents and surfactants.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne une composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure, et un composé contenu dans ladite composition.
EP15745431.5A 2014-07-30 2015-07-27 Composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure Pending EP3174390A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014110783.7A DE102014110783A1 (de) 2014-07-30 2014-07-30 Zusammensetzung zur Modulation der Aktivität von Nicht-Strukturproteinen
PCT/EP2015/067113 WO2016016168A1 (fr) 2014-07-30 2015-07-27 Composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure

Publications (1)

Publication Number Publication Date
EP3174390A1 true EP3174390A1 (fr) 2017-06-07

Family

ID=53776575

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15745431.5A Pending EP3174390A1 (fr) 2014-07-30 2015-07-27 Composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure

Country Status (5)

Country Link
US (2) US10233150B2 (fr)
EP (1) EP3174390A1 (fr)
CN (1) CN106714555B (fr)
DE (1) DE102014110783A1 (fr)
WO (1) WO2016016168A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4272554A1 (fr) * 2022-05-06 2023-11-08 Eberhard Karls Universität Tübingen Biocides et leurs liaisons adhésives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948943A (en) * 1973-05-03 1976-04-06 Boehringer Ingelheim Gmbh Aminocarboxylic acid higher alkylamides
DE19603977A1 (de) * 1996-02-05 1997-08-07 Henkel Ecolab Gmbh & Co Ohg Verfahren zur Reinigung und Desinfektion von empfindlichen medizinischen Geräten

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US126646A (en) * 1872-05-14 Improvement in dies for forming blanks for carriag-e-clips
DE2423389A1 (de) * 1974-05-14 1975-12-04 Hoechst Ag Arzneimittel mit psychotroper wirkung und verfahren zu ihrer herstellung
JPS5135433A (ja) 1974-09-18 1976-03-25 Ajinomoto Kk Satsuchuzaisoseibutsu
DE3410956A1 (de) 1984-03-24 1985-09-26 Henkel KGaA, 4000 Düsseldorf Antimikrobiell wirksame substanzen, ihre herstellung und ihre verwendung
JPH09315946A (ja) 1996-05-23 1997-12-09 Kao Corp 毛髪処理剤組成物
DE20017213U1 (de) * 2000-10-07 2000-12-21 Henkel Ecolab Gmbh & Co Ohg Milbizide
DE10064413A1 (de) * 2000-12-21 2002-07-11 Ecolab Gmbh & Co Ohg System zur Beschichtung von Fußböden
DE10300323A1 (de) 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20060257498A1 (en) * 2005-05-13 2006-11-16 Ecolab Inc. Antimicrobial combination of amine and oxygen compounds
JP5352100B2 (ja) 2008-03-12 2013-11-27 株式会社 資生堂 皮膚外用組成物
WO2012028196A1 (fr) * 2010-09-02 2012-03-08 Ecolab Inc. Désinfectants à base de glucoprotamine efficaces contre les prions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948943A (en) * 1973-05-03 1976-04-06 Boehringer Ingelheim Gmbh Aminocarboxylic acid higher alkylamides
DE19603977A1 (de) * 1996-02-05 1997-08-07 Henkel Ecolab Gmbh & Co Ohg Verfahren zur Reinigung und Desinfektion von empfindlichen medizinischen Geräten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016016168A1 *

Also Published As

Publication number Publication date
CN106714555B (zh) 2021-08-17
WO2016016168A1 (fr) 2016-02-04
CN106714555A (zh) 2017-05-24
US20170137379A1 (en) 2017-05-18
DE102014110783A1 (de) 2016-02-04
US10233150B2 (en) 2019-03-19
US10759752B2 (en) 2020-09-01
US20190161446A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CH645919A5 (de) Verfahren zur herstellung von lagerstabilen praeparationen von mikroorganismen und deren verwendung zum abbau industrieller syntheseprodukte.
DE102008056551A1 (de) Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
CN101967203A (zh) 寡聚酸碘及其制备方法与应用
CN101313673A (zh) 一种遗体防腐保存液及其制备方法和应用
Fry et al. Use of a substrate/alliinase combination to generate antifungal activity in situ
WO2001058446A1 (fr) Utilisation de solutes compatibles pour proteger des biopolymeres macromoleculaires contre une decomposition par des enzymes a pouvoir degradant
CN103609572B (zh) 一种含有四霉素与氨基寡糖素的杀菌组合物
WO2008040516A2 (fr) Composition microbiologique et son utilisation
DE10006578C2 (de) Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
CN105342869A (zh) 一种具有防腐功效的组合物及其制备方法和应用
Singh et al. The toxicity of four native Indian plants: Effect on AChE and acid/alkaline phosphatase level in fish Channa marulius
EP3174390A1 (fr) Composition pour moduler l'activité de protéines qui ne sont pas des protéines de structure
WO2011000572A1 (fr) Procédé et dispositif permettant de mettre en évidence des effets biologiques à long terme dans des cellules
CN102335128A (zh) 一种络合碘溶液的配方及制备方法
US11000541B1 (en) Medicine composition for facilitating treating organs of a mammal
CN111374899B (zh) 一种组合物及其制备方法和应用
Faris Taufeq et al. Potential Hemostatic and Wound Healing Effects of Thermoresponsive Wound Dressing Gel Loaded with Lignosus rhinocerotis and Punica granatum Extracts
Wohlrab Über die histochemische Erfaßbarkeit der Aminosäure-Dehydrogenasen in Säugetierorganen
DE102007032158A1 (de) Antitumormittel
Bairagi et al. Identification of Bacterial Population from Diabetic Wound of Mice to Study the Bactericidal Efficacy of Green Synthesized Silver Nanoparticle by Saraca asoca Bark Extract
DE10310196A1 (de) Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
WO2003047533A2 (fr) Composition pour le traitement de la surface de la peau
US6403111B1 (en) Method for preparing aqueous phytosphingosine solution
Karthick et al. Assessment of termite mound soil extract and its applications
Sartika et al. The effectiveness of hand sanitizer gel from hibiscus leaves and lime peel waste as an antimicrobial preparation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

17P Request for examination filed

Effective date: 20170130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190411

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS